Keyphrases
Diffuse Large B-cell Lymphoma (DLBCL)
84%
Israeli
84%
Lymphoma Patients
69%
Tertiary Care Hospital
66%
Diagnostic Performance
61%
Rituximab
60%
Intensive Chemotherapy
57%
Hospitalization
55%
Obinutuzumab
53%
Acute Myeloid Leukemia
53%
Midostaurin
53%
COVID-19 Pandemic
53%
Exosomal
53%
Italian Studies
53%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
53%
Chronic Myeloid Leukemia
53%
Human Telomerase Reverse Transcriptase (hTERT)
53%
Clinical Characteristics
53%
Leukemia Patients
46%
Multiple Myeloma
45%
Febrile Neutropenia
40%
Retrospective Analysis
38%
Positron Emission Tomography-computed Tomography (PET-CT)
38%
Multiple Myeloma Patients
37%
COVID-19
36%
Immunochemotherapy
36%
Relapsed or Refractory
35%
Patient Management
35%
Multicenter Retrospective Study
35%
Israel
34%
Anemia
34%
Chemotherapy
33%
Hematological Malignancies
31%
Patients with Hematological Malignancies
31%
Thrombocytopenia
31%
Response to Therapy
30%
Real-world Experience
30%
Italy
29%
Prevalence Characteristics
28%
Multivariate Analysis
28%
Skin Biopsy
26%
Blood Transfusion
26%
Novel Agents
26%
Second-generation Tyrosine Kinase Inhibitors
26%
Romidepsin
26%
Diarrhea Morbidity
26%
Hematopoietic Cell Transplantation
26%
18F-fluorodeoxyglucose Positron Emission Tomography (18F-FDG PET)
26%
Paraproteinemia
26%
Type 1 Diabetes Mellitus (T1DM)
26%
Medicine and Dentistry
Diseases
100%
Diffuse Large B-Cell Lymphoma
79%
Multiple Myeloma
79%
Retrospective Study
67%
Positron Emission Tomography-Computed Tomography
59%
COVID-19
53%
Acute Myeloid Leukemia
53%
Chronic Myelogenous Leukemia
53%
Hematologic Malignancy
53%
Telomerase Reverse Transcriptase
53%
Fluorodeoxyglucose F 18
53%
Biopsy Technique
53%
Messenger RNA
53%
Overall Survival
44%
Infection
36%
Thrombocytopenia
36%
Anemia
34%
Tyrosine-Kinase Inhibitor
32%
Prevalence
30%
Feces Culture
26%
Skin Biopsy
26%
Romidepsin
26%
Diabetes Mellitus
26%
Blood Transfusion
26%
Quality of Life
26%
Observational Study
26%
Belantamab Mafodotin
26%
Anticoagulation
26%
Liver Transplantation
26%
Infectious Complication
26%
Autologous Stem Cell Transplantation
26%
Lung Cancer
26%
Cancer Syndrome
26%
Steroid Treatment
26%
Non-Hodgkin Lymphoma
26%
Pulmonary Infiltrate
26%
Cell Transplantation
26%
Biological Marker
26%
Cutaneous T Cell Lymphoma
26%
Allogeneic Stem Cell Transplantation
26%
Positron Emission Tomography
26%
B-Cell Lymphoma
26%
Midostaurin
26%
Paraproteinemia
26%
Graft Failure
26%
Anthrax
26%
Patient Care
26%
Hereditary Nonpolyposis Colorectal Cancer
26%
Colon Carcinoma
26%
Hodgkin's Lymphoma
26%
Pharmacology, Toxicology and Pharmaceutical Science
Multiple Myeloma
84%
Diseases
69%
Infection
61%
Rituximab
60%
Obinutuzumab
53%
Hematologic Malignancy
53%
Telomerase Reverse Transcriptase
53%
Messenger RNA
53%
Retrospective Study
39%
Chemotherapy
34%
Cohort Study
33%
Overall Survival
33%
Thrombocytopenia
31%
Progression Free Survival
27%
Solid Lipid Nanoparticle
26%
Tumor Syndrome
26%
Diffuse Large B Cell Lymphoma
26%
Midostaurin
26%
Bortezomib
26%
Belantamab Mafodotin
26%
Graft Failure
26%
Anthrax
26%
Anemia
26%
Lung Infiltrate
26%
Biological Marker
26%
Atrial Fibrillation
26%
Lung Cancer
26%
Neutropenia
26%
Pandemic
26%
Fluorodeoxyglucose F 18
26%
Hereditary Nonpolyposis Colorectal Cancer
26%
Peroneus Nerve Paralysis
26%
Nonhodgkin Lymphoma
26%
Observational Study
26%
Romidepsin
26%
Remission
26%
Cutaneous T Cell Lymphoma
26%
Colon Carcinoma
26%
Peripheral T Cell Lymphoma
22%
Event Free Survival
18%
Malignant Neoplasm
18%
Remdesivir
17%
Adverse Event
15%
Mortality Rate
13%
Neuropathy
13%
Follicular Lymphoma
11%
T Cell Lymphoma
11%
Arterial Thromboembolism
10%
Disease Course
10%
Bleeding
10%